Trading of shares in Eqology AS
Cancellation of extraordinary general meeting in EQOLOGY AS – withdrawal of contemplated offer to shareholders
Reference is made to the notice published on 11 November 2020 that called for a general meeting in Eqology AS (“Eqology”) to resolve a de-listing of Eqology’s shares from NOTC during December 2020. ImmunoPharma AS (ImmunoPharma), which controls more than 2/3 of the outstanding shares in Eqology, requested a de-listing of Eqology’s shares. Due to feedback from certain minority shareholders, ImmunoPharma has requested the board of Eqology to cancel the extraordinary general meeting called for at Friday 20 November at 1 pm CET. Consequently, and in light of ImmunoPharma’s shareholding, the board of Eqology has today decided that said extraordinary general meeting is cancelled.
ImmunoPharma has further informed the board of Eqology that the contemplated offer for Eqology shares set forth in the notice on 6 November 2020 is withdrawn, and that ImmunoPharma will consider to offer to buy outstanding shares in Eqology following Eqology’s adoption of the annual accounts for 2020.
For questions regarding the cancellation of the general meeting, contact:
Chairman of the board
Call for extraordinary general meeting
Innkalling Ekstra ordinær Generalforsamling – Eqology AS – 20 november 2020
Offer to shareholders in Eqology
Eqology AS’s President Research, Development and Communication of health concepts Børre Gjersvik second-largest shareholder
Eqology AS’s President Research, Development and Communication of health concepts Børre Gjersvik has today acquired 7,000,000 shares in Eqology AS. He previously had 4,152,930 shares. This means that he now has 11,152,930 shares in Eqology AS, which means that he has become the company’s second-largest shareholder with 10, 2% of the company’s shares. In this connection, he states that he has great faith in the future of the company and its growth potential.
Quarterly, Half Year and Annual report Eqology AS: